CR20190310A - Compuestos de pirazolopirimidina y métodos de uso de los mismos - Google Patents
Compuestos de pirazolopirimidina y métodos de uso de los mismosInfo
- Publication number
- CR20190310A CR20190310A CR20190310A CR20190310A CR20190310A CR 20190310 A CR20190310 A CR 20190310A CR 20190310 A CR20190310 A CR 20190310A CR 20190310 A CR20190310 A CR 20190310A CR 20190310 A CR20190310 A CR 20190310A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- pyrazolopyrimidine compounds
- compounds
- kinase inhibitors
- pyrazolopyrimidine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En el presente documento se describen compuestos de fórmula (IA) o una sal farmacéuticamente aceptable de los mismos y métodos de uso como inhibidores de Janus cinasa.Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2016112932 | 2016-12-29 | ||
PCT/EP2017/084569 WO2018122212A1 (en) | 2016-12-29 | 2017-12-22 | Pyrazolopyrimidine compounds and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20190310A true CR20190310A (es) | 2019-08-21 |
Family
ID=61094385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20190310A CR20190310A (es) | 2016-12-29 | 2017-12-22 | Compuestos de pirazolopirimidina y métodos de uso de los mismos |
Country Status (18)
Country | Link |
---|---|
US (1) | US11155557B2 (es) |
EP (1) | EP3562809B1 (es) |
JP (1) | JP6900491B2 (es) |
KR (1) | KR20190100337A (es) |
CN (1) | CN110114343B (es) |
AU (1) | AU2017385543A1 (es) |
BR (1) | BR112019013287A2 (es) |
CA (1) | CA3046435A1 (es) |
CL (1) | CL2019001694A1 (es) |
CO (1) | CO2019006220A2 (es) |
CR (1) | CR20190310A (es) |
IL (1) | IL267671A (es) |
MA (1) | MA47167A (es) |
MX (1) | MX2019007339A (es) |
PE (1) | PE20191236A1 (es) |
PH (1) | PH12019501022A1 (es) |
RU (1) | RU2019123319A (es) |
WO (1) | WO2018122212A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20190100337A (ko) | 2016-12-29 | 2019-08-28 | 에프. 호프만-라 로슈 아게 | 피라졸로피리미딘 화합물 및 이의 사용 방법 |
CR20190520A (es) | 2017-05-22 | 2020-01-21 | Hoffmann La Roche | Composiciones y compuestos terapéuticos y métodos para utilizarlos |
CN111587250A (zh) * | 2018-01-15 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 作为jak抑制剂的吡唑并嘧啶化合物 |
CN114008051A (zh) | 2019-06-18 | 2022-02-01 | 豪夫迈·罗氏有限公司 | Jak激酶的吡唑并嘧啶砜抑制剂及其用途 |
EP3986899A1 (en) * | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
CN114026096A (zh) * | 2019-06-18 | 2022-02-08 | 豪夫迈·罗氏有限公司 | 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途 |
WO2022175829A1 (en) * | 2021-02-17 | 2022-08-25 | Cellix Bio Private Limited | Topical formulations and compositions |
WO2024052512A1 (en) * | 2022-09-09 | 2024-03-14 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
WO2024052513A1 (en) * | 2022-09-09 | 2024-03-14 | Chiesi Farmaceutici S.P.A. | Heterocyclic derivatives as janus kinase inhibitors |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
AU6311996A (en) | 1995-07-06 | 1997-02-05 | Zeneca Limited | Peptide inhibitors of fibronectine |
US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
JP4486817B2 (ja) | 2001-12-20 | 2010-06-23 | バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト | 1,4−ジヒドロ−1,4−ジフェニルピリジン誘導体 |
SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
CA2727036C (en) | 2008-06-20 | 2017-03-21 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
MX2016015062A (es) * | 2014-05-23 | 2017-02-27 | Hoffmann La Roche | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina los cuales son inhibidores de janus cinasas (jak). |
TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
CN108473501B (zh) | 2016-02-18 | 2021-07-16 | 豪夫迈·罗氏有限公司 | 治疗化合物、其组合物及使用方法 |
TN2018000452A1 (en) | 2016-06-29 | 2020-06-15 | Hanmi Pharm Ind Co Ltd | Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof |
KR20190100337A (ko) | 2016-12-29 | 2019-08-28 | 에프. 호프만-라 로슈 아게 | 피라졸로피리미딘 화합물 및 이의 사용 방법 |
-
2017
- 2017-12-22 KR KR1020197022055A patent/KR20190100337A/ko not_active Application Discontinuation
- 2017-12-22 MA MA047167A patent/MA47167A/fr unknown
- 2017-12-22 CN CN201780081495.7A patent/CN110114343B/zh active Active
- 2017-12-22 CA CA3046435A patent/CA3046435A1/en not_active Abandoned
- 2017-12-22 BR BR112019013287A patent/BR112019013287A2/pt not_active Application Discontinuation
- 2017-12-22 MX MX2019007339A patent/MX2019007339A/es unknown
- 2017-12-22 PE PE2019001227A patent/PE20191236A1/es unknown
- 2017-12-22 CR CR20190310A patent/CR20190310A/es unknown
- 2017-12-22 JP JP2019535901A patent/JP6900491B2/ja active Active
- 2017-12-22 EP EP17836033.5A patent/EP3562809B1/en active Active
- 2017-12-22 WO PCT/EP2017/084569 patent/WO2018122212A1/en unknown
- 2017-12-22 AU AU2017385543A patent/AU2017385543A1/en not_active Abandoned
- 2017-12-22 RU RU2019123319A patent/RU2019123319A/ru not_active Application Discontinuation
-
2019
- 2019-05-08 PH PH12019501022A patent/PH12019501022A1/en unknown
- 2019-06-14 CO CONC2019/0006220A patent/CO2019006220A2/es unknown
- 2019-06-19 CL CL2019001694A patent/CL2019001694A1/es unknown
- 2019-06-25 US US16/452,058 patent/US11155557B2/en active Active
- 2019-06-26 IL IL267671A patent/IL267671A/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN110114343A (zh) | 2019-08-09 |
MX2019007339A (es) | 2019-09-06 |
US20190345165A1 (en) | 2019-11-14 |
CO2019006220A2 (es) | 2019-06-28 |
AU2017385543A1 (en) | 2019-05-23 |
BR112019013287A2 (pt) | 2019-12-24 |
KR20190100337A (ko) | 2019-08-28 |
MA47167A (fr) | 2019-11-06 |
CN110114343B (zh) | 2022-09-06 |
IL267671A (en) | 2019-08-29 |
JP2020503339A (ja) | 2020-01-30 |
WO2018122212A1 (en) | 2018-07-05 |
CL2019001694A1 (es) | 2019-11-22 |
US11155557B2 (en) | 2021-10-26 |
RU2019123319A (ru) | 2021-02-01 |
PH12019501022A1 (en) | 2019-12-16 |
RU2019123319A3 (es) | 2021-02-01 |
EP3562809B1 (en) | 2021-06-09 |
PE20191236A1 (es) | 2019-09-11 |
JP6900491B2 (ja) | 2021-07-07 |
EP3562809A1 (en) | 2019-11-06 |
CA3046435A1 (en) | 2018-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019006220A2 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos | |
CL2019002032A1 (es) | Procesos para preparar un inhibidor de jak1 (divisional de solicitud 1790-2018). | |
DOP2018000088A (es) | Amidas heterocíclicas como inhibidores de cinasas | |
EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
CO2017011754A2 (es) | Amidas heterocíclicas como inhibidores de quinasa | |
NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
NI201600152A (es) | Compuestos de heteroarilo o arilo bicíclicos fusionados y su uso como inhibidores de irak4 | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
ECSP17054980A (es) | Inhibidores selectivos de bace1 | |
ECSP15043696A (es) | Compuestos de heteroarilo y sus usos | |
CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
AR095039A1 (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
EA201692338A1 (ru) | Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы | |
NI201900077A (es) | Inhibidores selectivos de jak1 | |
CR20160070A (es) | Compuestos de triazolopiridina, composiciones y métodos de uso de los mismos | |
CY1122423T1 (el) | Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1 | |
MX2015013224A (es) | Inhibidores macrociclicos y biciclicos del virus de la hepatitis c. | |
CO2019005165A2 (es) | Compuesto de piridona como inhibidor de c-met | |
EA201792320A1 (ru) | Способ лечения рака ингибитором пути stat3 и ингибитором киназы | |
EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
ECSP19013196A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
EA201791596A1 (ru) | Пиразоловые соединения | |
CR20160539A (es) | Compuestos de 2-cloro-2difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos |